Conference Reports for NATAP

IAS 2015: 8th IAS Conference on HIV Pathogenesis Treatment and Prevention Vancouver, Canada 18-22 July 2015 Back

HCV/HIV Coinfection at IAS Vancouver 2015 July 19-23       IAS: C-EDGE CO-INFECTED: Phase 3 Study of Grazoprevir / Elbasvir in Patients with HCV/HIV - (07/22/15)   IAS: Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1 - (07/24/15)   IAS: Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1 - (07/24/15)   IAS: More Diabetes and CVD, Shorter Survival, in HIV/HCV-Positives With Steatosis (07/22/15)   IAS: Abbvie 3D in HCV/HIV Update ......HIGH SVR RATES IN HCV/HIV-1 CO-INFECTED PATIENTS REGARDLESS OF BASELINE CHARACTERISTICS........(note IDUs had 100% SVR) - (07/22/15)   IAS: DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HIV-HCV COINFECTION: INTERIM ANALYSIS OF A FRENCH MULTICENTER COMPASSIONATE USE PROGRAM (AI444-258) - (07/22/15)   IAS: Ledipasvir/sofosbuvir for 12 Weeks in Patients Coinfected With HCV and hiv-1: ION-4 - (07/22/15)   IAS: Frequent Fibrosis Regression With SVR in HCV/HIV+, Cutting Death Risk - (07/28/15)